This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Although interferon (IFN) β has many adverse effects, including flulike illness, increased spasticity, and laboratory abnormalities,1 autoimmune events are usually limited to autoantibodies with the thyroid the most common target organ involved.2 Liver abnormalities during IFN β therapy are usually clinically asymptomatic and transient biochemical events.1,2⇓ We report a patient who developed acute fulminant liver failure a few weeks after the initiation of IFN β and required an emergency liver transplant. Fulminant failure as a result of IFN β is not well reported in the MS literature and this is the first patient reported who required a liver transplant as a result of MS therapy.
Case report.
A 59-year-old Caucasian woman was transferred to the Intensive Care Unit (ICU) in hepatic coma and hepatorenal syndrome 7 weeks after starting interferon β-1a (Rebif, Serono-Canada, Oakville, Ontario, Canada). One year previously, she developed diplopia and ataxia. An MRI scan disclosed small deep white matter …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Topics Discussed
Alert Me
Recommended articles
Fatal acute liver failure with hepatitis B virus infection during natalizumab treatment in multiple sclerosis
Reversible periodic alternating gaze deviation in hepatic encephalopathy
Modulation of neural activation following treatment of hepatic encephalopathy
Unmasking of autoimmune hepatitis in a patient with MS following interferon beta therapy